In AML, R882H mutations of DNMT3A leads to reduced DNA methylation at enhancer regions and activation of self-renewal gene programs, which is highly recurrent in AML and commonly related to poor risk disease [124–126]. Here, DNMT3A is linked to acute myeloid leukemia.